Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

@article{Simon2012PreliminaryIO,
  title={Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.},
  author={George Rajan Simon and Michael J. Schell and Mubeena Begum and Jongphil Kim and Alberto Alejandro Chiappori and Eric B. Haura and Scott J. Antonia and Gerold Bepler},
  journal={Cancer},
  year={2012},
  volume={118 9},
  pages={2525-31}
}
BACKGROUND Excision repair cross complementing 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) are molecular determinants that predict sensitivity or resistance to platinum agents and gemcitabine, respectively. Tailored therapy using these molecular determinants suggested patient benefit in a previously reported phase 2 trial. Here, we report an individual patient analysis of prospectively accrued patients who were treated with the "personalized therapy" approach versus other "standard… CONTINUE READING
18 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

( NSCLC ) who are 70 years of age or older

  • AA Chiappori, E Haura, FA Rodriguez
  • 2008

Similar Papers

Loading similar papers…